

COVAX

CEPI



unicef



COVAX Allocation Round 8/9 NEW Vaccine Allocation Decision

IAVG Meeting on 13 October 2021

Table of Contents

Background

- ☐ Purpose & Allocation Methodology for Round 8/9
- ☐ Round 8/9 Participant Scope
- ☐ Round 8/9 Supply Scope

Round 8/9 Proposal

- ☐ Round Outcome - Allocations
- ☐ Descriptive Statistics Summary
- ☐ Overview Graphs
- ☐ Distribution Proposal & Shipment Considerations
- ☐ Conclusions
- ☐ Signatures

IAVG Opinions

- ☐ IAVG Opinions on Current and Future Allocations

Annex 1

- ☐ Overview of Allocations to date
- ☐ Dose Donations before Round 8/9
- ☐ Reallocations Before Rounds 7&8/9

Background: Round 8/9 Supply and Demand

Background

Context for COVAX Allocation Round 8/9

Context for Round 8/9

1/3

Context & Purpose

- COVAX Allocation Round 8/9 aims to allocate Q4-2021 supply that has been confirmed to date to be available for shipment during November and December 2021. Further rounds may be conducted as additional information is received on Q4 supply availability.
- An exceptional round (R7) was run prior to COVAX Allocation Round 8/9, with the objective of dedicating available supply in October to COVAX Participants with low vaccination coverage (below 15% total coverage from all sources) and with the ability to absorb additional doses in a short timeframe.
- Due to vaccine supply changes and uncertainties, Round 8/9 was initially approved by the IAVG on 01 October but subsequently cancelled and rerun for final IAVG approval on 13 October.
- COVAX Allocation Round 8/9 and Round 7 provide countries with visibility on allocations through the end of 2021, based on the current information available on confirmed vaccine supply to COVAX for this period.
- This current allocation round is run in two parts: a first step to allocate 50% of supply to countries below 20% COVAX coverage which is denoted as R8 in the Portal, and a second step to allocated 50% of supply to countries with a low coverage accounting for all sources of supply (20% total coverage threshold) which is denoted as R9 in the Portal. Therefore, the JAT refers to the present round as COVAX Allocation Round 8/9.
- The methodology represents an effort by the COVAX partners to target a segment of overall supply available for allocation during the last quarter of 2021 to Facility Participants for whom data suggests that COVAX is either the only or the primary source of COVID-19 vaccines, while ensuring that all Participants eligible to receive an allocation through COVAX are included in the round.
- In Round 8/9, 2,671,200 doses (1-dose regime) were allocated to the Humanitarian Buffer.
- Due to timing for necessary reallocation of 2.9M doses of Sinopharm not absorbed by the Humanitarian Buffer in Q3-2021, as well as incoming refusals for volumes of Pfizer, Moderna, and Sinopharm from preceding allocation rounds, the JAT decided to include these doses in the current allocation round to be able to leverage the algorithm to determine where these doses should be reallocated. These reallocated doses are added to the R8/9 supply and are included in the Round's achieved coverage.

Context for Round 8/9

2/3

Allocation Approach

- A decision was taken to activate the round delay toggle for all Facility Participants falling into the high-income countries (HICs) income bracket with above 40% total population coverage from all sources, thereby making these Participants wait until Q1-2022 to be served by the Facility.¹ The 40% threshold was defined to align with the WHO Covid-19 Global Vaccination Strategy.
- However, since the allocation mechanism is allocating supply available in Q4-2021 the Office of the COVAX Facility has the obligation to implement the contractual agreement with Optional (OP) and Committed Participants (CP) for deals closing at the end of 2021.
- This varies on a product basis and is subject to volumes available for Q4-2021.

Confirmation of Requested Doses by Optional Participants for Deals Ending in December 2021

- At this stage, pro-rata share calculations and outreach to Self-Financing Participants (SFP) have been finalized, and outstanding demand was confirmed for these Participants for the remainder of the year.
- Only OPs that confirmed their wish to receive the remainder of their pro-rata share for deals they have opted in-to were serviced through an administrative round before this current Round 8/9 (please see next slide for more details).

1. An exception was made for HICs eligible for a standard COVAX Allocation and with lower than 40% total population coverage from all sources of supply which were non-donors (namely Trinidad and Tobago).

Context for Round 8/9

3/3

Overview of Administrative Rounds Executed before R8/9

Administrative rounds are occasionally needed to be executed in the WHO Allocation Portal. Administrative rounds are intended to address swift operational issues for a limited number of doses which must be quickly allocated to Participants due to a variety of reasons, including short shelf-life issues, closing out Optional Purchaser (OP) SFPs, and some cost-sharing doses procured exceptionally by some Participants.

- **ADMIN-3 (5 participants, 7,996,800 doses of AZ)** addresses doses with a short shelf life that needed immediate allocation. They were offered by COVAX to specific participants that could absorb them in such short timeframe.
- **ADMIN-4 (4 participants, 14,769,800 doses of Sinopharm/Sinovac)** was configured to include SFP coverage from residual doses after the completion of a Sinopharm and Sinovac cost-sharing round. Before the order could be executed, COVAX had to provide a list of all buyers. Once it was confirmed that there was insufficient AMC demand due to financing issues, there was just over a week to finalize the deal, which was insufficient for determining a final list of recipients, so the offer was directed to SFPs.
- **ADMIN-5 (2 participants, 1,167,660 doses of Pfizer)** was configured to close out pro rata shares for 2 OP participants that wanted to receive their remaining doses of Pfizer as the deal is expiring in 2021.
- **ADMIN-6 (2 participants, 714,000 doses of Sinovac)** addresses the purchase of Sinovac doses by 2 OP participants that go above their initial pro rata share for the deal.

Background

Participant Scope

Participant Scope
COVAX Facility Participants <ul style="list-style-type: none">There are 89 Advance Market Commitment (AMC) and 73 Self Financing (SFP) participants to the COVAX Facility.²
Participant Allocation Preferences <ul style="list-style-type: none">In advance of Rounds 7 and 8/9, COVAX Facility Participants were invited to update their allocation and round-specific preferences on the COVAX Collaboration Platform (CCP). For the first time, ahead of these rounds, Participants were asked to express direct product preferences for all the vaccines in the COVAX Facility portfolio.The JAT decided to ensure participants would not be assigned a vaccine marked as "highly undesirable" by removing this vaccine from the possible ones to be allocated to that Participant.Additionally, Participants were also invited to provide a voluntary monthly allocation maximum, as well as an ultra-cold chain vaccine allocation maximum through the CCP.As mentioned in slide 5, HICs are not included in this round and feature in the group of Participants who have used the voluntary delay toggle.
Context: Reallocation Supply Not Run through Algorithm in R8/9 <ul style="list-style-type: none">Syrian Arab Republic is allocated 224,400 doses of Sinovac vaccine that is not allocated in this Round but which will be processed through reallocation.Another Participant confirmed no absorptive capacity for further doses in Q4-2021 but did so after the window closed to activate the round skip toggle.

Eligible Participant Summary	
Criteria	Participants (n)
Inclusion	
AMC	89
OP	39
CP	31
Team Europe	3
Total Inclusion	162
Exclusion	
20% population coverage (or requested) reached through COVAX	27
Voluntary Delay Toggle	36
OP Participant Opt-Outs	6
Participant excluded due to confirmation from country of no absorptive capacity	1
Other Cases	
Participant will be served through reallocation of Sinovac doses	1
Total Participants without Nov-Dec Allocation	71

2. 89 AMC participants out of 92 eligible economies have joined the Covax facility. The 3 AMC-eligible economies who have not joined may do so at any time.SFP participants total is 102 broken down as follows. Optional Purchase=42, Committed Purchase= 30, Team Europe = 30 (European Commission is counted as a participant). This brings us to a total of 191. However, when counting the total Covax participants we count all the eligible AMC92. SFPs. and USA =195.

Background

COVAX Allocation Round 8/9 Supply

Round Supply Considerations

- COVAX Allocation Round 8/9 is for November and December 2021 confirmed supply. Additional rounds will be conducted should further supply be made available through COVAX in Q4-2021.
- COVAX Allocation Round 8/9 and Round 7 are communicated to participants around the same time to provide them with visibility on allocations through the end of 2021, based on current supply knowledge.³
- Though R7 & R8/9 were run separately to allow the JAT to dedicate October supply and half of November through December supply to those Participants with low coverage, these two rounds should be viewed holistically as allocating confirmed Q4-2021 supply.

Minimum Shipment Size

Product Name	Minimum Shipment Size (doses)
AstraZeneca – Vaxzevria	• 2,400
Janssen - Ad26.COV 2-S	• 151,200 Participants >5M pop • 7,200 Participants <5M pop
Pfizer BioNTech – Comirnaty (APA)	• 1,170
Pfizer BioNTech – Comirnaty (USG-facilitated)	• 1,170
Moderna – mRNA-1273	• 188,160 • Exceptional 10,080 <5M pop
Sinopharm BIBP	• 20,400 Participants >1M pop • 3,600 Participants <1M pop

Overview of November-December Available Supply

Product Name	Total Supply Nov-21 (doses)	Total Supply Dec-21 (doses)	Total Supply Nov & Dec-21 (doses)
AstraZeneca – Vaxzevria		20,100,000	20,100,000
Janssen - Ad26.COV 2-S	2,923,200		2,923,200
Pfizer BioNTech – Comirnaty (APA)	5,032,170	5,032,170	10,064,340
Pfizer BioNTech – Comirnaty (USG-facilitated)	36,168,210	36,398,700	72,796,230
Moderna – mRNA-1273	11,874,240	11,874,240	23,748,480
Sinopharm BIBP	4,176,000	4,179,600	8,355,600
TOTAL	70,453,140	67,534,710	137,987,850

3. Information on supply availability was provided to the JAT by the COVAX Procurement Coordinator, UNICEF SD.

Background

COVAX Allocation Round 8/9 Supply

Round Supply Considerations

- Due to the two steps⁴ required to execute the approved allocation methodology, the supply needed to be divided.
- Furthermore, from the total supply available under the Pfizer APA, 8,003,970 doses are withheld across Q4-2021 to ensure potential demand from OPs can be honored before the end of the year and of the deal (*Refer to pro-rata share on slide 5*). This amount was removed from the quantities of Pfizer APA doses allocated in step 1 (R8). As a result, step 2 (R9) only allocated USG-facilitated Pfizer doses.
- Finally, the amount of HB doses due for Nov-Dec is taken out of the JnJ vaccine. Due to the one-dose regimen and the minimum batch size, this amount is 2,671,200 doses.

Round ID	Product	Doses Allocated (n)	Participant Receiving (n)
R8 step 1 (R8)	AZ (APA)	10,048,800	18
R8 step 1 (R8)	J&J (APA)	1,461,600	13
R8 step 1 (R8)	Pfizer (APA)	10,064,340	11
R8 step 1 (R8)	Pfizer (USG 500M)	35,777,430	39
R8 step 1 (R8)	Moderna (APA)	11,860,800	16
R8 step 1 (R8)	Sinopharm (APA)	4,173,600	10
Total Supply for Step 1 (R8)		73,386,570	91
R8 step 2 (R9)	AZ (APA)	10,051,200	12
R8 step 2 (R9)	J&J (APA)	1,461,600	4
R8 step 2 (R9)	Pfizer (APA)	-	0
R8 step 2 (R9)	Pfizer (USG 500M)	34,855,470	20
R8 step 2 (R9)	Moderna (APA)	11,854,080	6
R8 step 2 (R9)	Sinopharm (APA)	4,161,600	6
Total Supply for Step 2 (R9)		62,383,950	37
Total Overall (R8/9)		135,770,520⁵	91

4. Step 1 (R8) allocated 50% of confirmed November and December supply to all participants below 20% COVAX coverage. Step 2 (R9) dedicated 50% of the supply to participants below 20% total population coverage from all sources.

5. An additional 2,163,330 doses of the USG-facilitated Pfizer supply could not be allocated through the present allocation round due to some Participants' confirmed lack of absorption capacity to receive doses of this product. These doses will be reallocated to Facility Participants willing and able to accept these doses during the round's standard reallocation process.

Background

Humanitarian Buffer

Proposed Allocation to the Humanitarian Buffer	
Product Name	Total Supply (doses)
Janssen - Ad26.COV 2-S	2,671,200

Background to Proposed Allocation to the Humanitarian Buffer
<ul style="list-style-type: none">As per the GAVI Board decision to make up to 5% of available supply from COVAX APA-secured deals available to the COVAX Humanitarian Buffer (HB), the total amount owed to the HB from COVAX Allocation Rounds 1-8/9 is 19,423,704 doses (2-dose regime).To date, and as the result of R6 (re-) allocation and R7, a total amount of 14,086,400 Sinopharm doses is already available to the HB.To ensure that the HB receives the full amount of what is owed from R1-R8/9, the JAT proposes to allocate the outstanding amount of 5,337,394 doses (2-dose regime, corresponding to 2,668,652 courses) to the HB in R8.A 1-dose regime vaccine without Ultra Cold Chain (UCC) requirements like the J&J vaccine is certainly the preferred vaccine in hard-to-access humanitarian settings.Against that background, and taking the J&J batch size into account, the JAT expects to allocate a total amount of 2,671,200 J&J doses to the HB in R8/9.

Background

Additional Resources in the Annex

Resources in Annex 1

- Annex 1 includes an overview of all allocations, donations, and post-allocation adjustments made in the Allocation Portal.
- Ahead of running Round 7, around 8 million doses of Pfizer vaccine from Round 5 and 32.6 million doses from Round 6 were reallocated to 27 and 32 participants respectively (see details in the annex). This continues to have effects in this R8/9.
- Furthermore, dose donations for a total of **162,631,850** were also considered, including dose donations that have taken place since finalizing Round 7 (see annex).

R8/9 Outcome

R8/9 Outcome

Major differences in the format of Round 8/9 output compared to previous rounds

Interpreting the R8/9 Outcome

- Due to the two steps⁶ required to execute the approved allocation methodology, there are two outputs presented in the Allocation Portal, as well as in the slides that follow.
- This is due to the fact that the output of the first step (i.e. allocating 50% of the supply to all participants according to the standard methodology, the allocation proportional to population size) needs to serve as an input for the following step (i.e. allocating the remaining 50% of supply only to Participants with an overall population coverage from all sources of supply below 20%).
- In the table in slides 14-18, you can find the final allocation for Round 8/9 to each Participant, represented as the sum of the allocations received across the two steps.
- As mentioned on slide 5, the algorithm was leveraged in this present round to reallocate 2.9M doses of Sinopharm not absorbed by the Humanitarian Buffer in Q3-2021, as well as incoming refusals for volumes of Pfizer, Moderna, and Sinopharm from preceding allocation rounds. These doses were reallocated to the R8/9 overall supply and are included in the Round's achieved coverage.
- Syrian Arab Republic is allocated 224,400 doses of Sinovac vaccine that is not allocated in this Round but which will be processed through reallocation.

6. Step 1 (R8) allocated 50% of confirmed November and December supply to all participants below 20% COVAX coverage. Step 2 (R9) dedicated 50% of the supply to participants below 20% total population coverage from all sources.

R8/9 Allocation Outcome (1 of 5)

Participant Name	WHO Region	Participation Model	Doses allocated of AstraZeneca	Doses allocated of J&J	Doses allocated of Moderna	Doses allocated of Pfizer APA	Doses allocated of Pfizer USG	Doses allocated of Sinopharm	Sum of Total Doses Allocated R8/9
Afghanistan	EMR	AMC92	2,097,600						2,097,600
Albania	EUR	OPTIONAL	72,000	14,400					86,400
Algeria	AFR	AMC92	662,400	151,200					813,600
Angola	AFR	AMC92					1,753,830		1,753,830
Argentina	AMR	OPTIONAL	100,800						100,800
Armenia	EUR	OPTIONAL	26,400	50,400					76,800
Azerbaijan	EUR	COMMITTED				1,344,330			1,344,330
Bangladesh	SEAR	AMC92			564,480		9,668,880		10,233,360
Belize	AMR	COMMITTED				79,560			79,560
Benin	AFR	AMC92			1,317,120				1,317,120
Bosnia and Herzegovina	EUR	COMMITTED						102,000	102,000
Botswana	AFR	OPTIONAL					100,620		100,620
Brazil	AMR	OPTIONAL	2,625,600	302,400					2,928,000
Burkina Faso	AFR	AMC92	273,600		376,320		1,998,360		2,648,280
Cambodia	WPR	AMC92			188,160				188,160
Cameroon	AFR	AMC92			3,010,560		799,110		3,809,670
Central African Republic	AFR	AMC92			90,720				90,720
Chad	AFR	AMC92			188,160				188,160
Colombia	AMR	COMMITTED				150,930			150,930

R8/9 Allocation Outcome (2 of 5)

Participant Name	WHO Region	Participation Model	Doses allocated of AstraZeneca	Doses allocated of J&J	Doses allocated of Moderna	Doses allocated of Pfizer APA	Doses allocated of Pfizer USG	Doses allocated of Sinopharm	Sum of Total Doses Allocated R8/9
Comoros	AFR	AMC92		43,200	120,960				164,160
Congo	AFR	AMC92					249,210		249,210
Costa Rica	AMR	OPTIONAL		151,200					151,200
Côte d'Ivoire	AFR	AMC92					1,634,490		1,634,490
Democratic People's Republic of Korea	SEAR	AMC92	2,092,800						2,092,800
Democratic Republic of the Congo	AFR	AMC92			1,881,600				1,881,600
Djibouti	EMR	AMC92					29,250		29,250
Dominica	AMR	AMC92			30,240				30,240
Ecuador	AMR	COMMITTED				1,008,540			1,008,540
Egypt	EMR	AMC92					3,892,590		3,892,590
Ethiopia	AFR	AMC92	4,178,400				3,360,240		7,538,640
Fiji	WPR	AMC92			50,400				50,400
Gabon	AFR	COMMITTED					101,790		101,790
Georgia	EUR	OPTIONAL		64,800					64,800
Ghana	AFR	AMC92					3,472,560		3,472,560
Guatemala	AMR	COMMITTED				273,780			273,780
Guinea	AFR	AMC92					299,520		299,520
Guyana	AMR	AMC92					42,120		42,120
Indonesia	SEAR	AMC92					13,837,590		13,837,590

R8/9 Allocation Outcome (3 of 5)

Participant Name	WHO Region	Participation Model	Doses allocated of AstraZeneca	Doses allocated of J&J	Doses allocated of Moderna	Doses allocated of Pfizer APA	Doses allocated of Pfizer USG	Doses allocated of Sinopharm	Sum of Total Doses Allocated R8/9
Iran (Islamic Republic of)	EMR	OPTIONAL	26,400						26,400
Iraq	EMR	COMMITTED				1,632,150		306,000	1,938,150
Jamaica	AMR	COMMITTED		50,400					50,400
Kenya	AFR	AMC92			564,480		2,886,390		3,450,870
Kyrgyzstan	EUR	AMC92					49,140	142,800	191,940
Lebanon	EMR	COMMITTED				771,030			771,030
Liberia	AFR	AMC92					136,890		136,890
Libya	EMR	OPTIONAL					459,810		459,810
Madagascar	AFR	AMC92						673,200	673,200
Malawi	AFR	AMC92					700,830		700,830
Malaysia	WPR	OPTIONAL	182,400	453,600					636,000
Mali	AFR	AMC92	499,200						499,200
Mauritania	AFR	AMC92		50,400					50,400
Mauritius	AFR	COMMITTED					107,640		107,640
Mexico	AMR	OPTIONAL	3,912,000						3,912,000
Montenegro	EUR	OPTIONAL		21,600					21,600
Morocco	EMR	AMC92					1,599,390		1,599,390
Mozambique	AFR	AMC92	307,200					1,305,600	1,612,800
Myanmar	SEAR	AMC92		1,512,000					1,512,000

R8/9 Allocation Outcome (4 of 5)

Participant Name	WHO Region	Participation Model	Doses allocated of AstraZeneca	Doses allocated of J&J	Doses allocated of Moderna	Doses allocated of Pfizer APA	Doses allocated of Pfizer USG	Doses allocated of Sinopharm	Sum of Total Doses Allocated R8/9
Namibia	AFR	COMMITTED		36,000			259,740		295,740
Nepal	SEAR	AMC92			188,160				188,160
Niger	AFR	AMC92	331,200					1,407,600	1,738,800
Nigeria	AFR	AMC92			12,230,400		11,999,520		24,229,920
North Macedonia	EUR	COMMITTED				100,620			100,620
occupied Palestinian territory, including east Jerusalem									
	EMR	AMC92					101,790		101,790
Pakistan	EMR	AMC92					2,225,340		2,225,340
Panama	AMR	COMMITTED				589,680			589,680
Paraguay	AMR	COMMITTED				301,860			301,860
Peru	AMR	COMMITTED				3,811,860			3,811,860
Philippines	WPR	AMC92					301,860		301,860
Republic of Moldova	EUR	AMC92	50,400		50,400				100,800
Rwanda	AFR	AMC92					301,860		301,860
Sao Tome and Principe	AFR	AMC92			40,320				40,320
Senegal	AFR	AMC92					599,040		599,040
Serbia	EUR	OPTIONAL	100,800						100,800
Sierra Leone	AFR	AMC92	148,800					102,000	250,800
South Sudan	AFR	AMC92	79,200						79,200
Sri Lanka	SEAR	AMC92					187,200		187,200

R8/9 Allocation Outcome (5 of 5)

Participant Name	WHO Region	Participation Model	Doses allocated of AstraZeneca	Doses allocated of J&J	Doses allocated of Moderna	Doses allocated of Pfizer APA	Doses allocated of Pfizer USG	Doses allocated of Sinopharm	Sum of Total Doses Allocated R8/9
Sudan	EMR	AMC92	2,083,200				2,398,500		4,481,700
Suriname	AMR	OPTIONAL		21,600					21,600
Tajikistan	EUR	AMC92					198,900		198,900
Togo	AFR	AMC92					301,860		301,860
Trinidad and Tobago	AMR	COMMITTED	100,800						100,800
Tunisia	EMR	AMC92					301,860		301,860
Uganda	AFR	AMC92					2,919,150		2,919,150
Ukraine	EUR	AMC92			2,446,080			1,387,200	3,833,280
United Republic of Tanzania	AFR	AMC92			376,320				376,320
Uzbekistan	EUR	AMC92					301,860		301,860
Vanuatu	WPR	AMC92						32,400	32,400
Viet Nam	WPR	AMC92					239,850	61,200	301,050
Yemen	EMR	AMC92	148,800						148,800
Zambia	AFR	AMC92					814,320	204,000	1,018,320
Zimbabwe	AFR	AMC92						2,611,200	2,611,200
Grand Total			20,100,000	2,923,200	23,714,880	10,064,340	70,632,900	8,335,200	135,770,520

Distribution Proposal & Shipment Considerations

COVAX Allocation Round 8/9

Distribution Proposal

- The **median** cumulative coverage from Rounds 1 to 9 for these same 91 participants is **13.10%**.
- After Round 9, the **median** cumulative coverage for these same 153 participants is **14.41%**.
- In alignment with the standard reallocation process, Participants will be notified that they are allotted a four-week period to clear all post-allocation preparedness checks following notification of the Round's outcome.
- Subsequent changes to Participants' total coverage from this Round resulting from the standard reallocation process will be communicated to the Participants upon execution. These modifications will also be visible to the IAVG in the Allocation Portal once completed.

Shipment Considerations

- Normally, to facilitate logistics planning, a prioritized shipping order is recommended for distribution of doses allocated in a Round. In previous rounds, a decision was taken to inform the sequencing of shipments based on participants' overall achieved coverage (from all source of supply) and their epidemiological situation. The JAT will provide this data to the Procurement Coordinator, as we have in the last rounds.
- The Joint Allocation Taskforce continues to work with the Procurement Coordinator and Procurement Agencies to account for the changing context in Facility Participants, particularly relating to absorptive capacity, upcoming shipments for donations, and additional doses coming from cost-sharing deals.
- The Facility recommends that, closer to the date of the planned shipment, participants' absorption capacity be assessed to ensure all the planned quantities can be used by participants within the vaccines' expiry dates.

Conclusion & Signatures

COVAX Allocation Round 8/9

Conclusion
<p>On 13 October 2021 the IAVG validated the allocation amounts detailed in Allocation Round Results (slides 14-18) and outlined in the Round 8 Output from the Allocation Portal. The JAT will provide further data and needed details as requested by the IAVG during the discussion.</p> <p>All Members of the IAVG were present at the decision-making meeting apart from two who excused themselves: Ms Maria Guevara, Dr Dafrossa Lyimo.</p>

Next Steps	
Process Step	Date
JAT sends R8/9 allocation proposal to IAVG	12 October 2021
IAVG Decision Meeting for R8/9	13 October 2021
WHO DDG sign-off on R8/9 allocation decision	13 October 2021
JAT notifies the Office of the COVAX Facility and the Procurement Coordinator	14 October 2021
Country communications dispatched for R8/9	14 October 2021

Signatures	
Signature Assistant Director General, Access to Medicines and Health Products, WHO	Signature Managing Director, Office of the COVAX Facility, Gavi
Approval obtained via email	Approval obtained via email
Mariângela SIMÃO	Aurélia NGUYEN
On date: 12 October 2021	On date: 12 October 2021

IAVG Opinion

On the JAT Proposed Allocation

The IAVG considered the JAT's allocation proposal and is of the following opinion:

- The IAVG agreed with the allocation methodology for the eighth allocation round (Round 8/9), which was:
 - ☐ To serve Facility Participants relying either solely or primarily on COVAX to access COVID-19 vaccines, and thereby activate the round skip toggle for HIC Participants.
 - ☐ To run the allocation round in two steps, in which half of the supply was allocated to all non-HIC Participants eligible for a standard allocation round (meaning below 20% COVAX coverage) and the other half of the supply was targeted to Facility Participants who remain behind in terms of coverage (meaning below 20% overall coverage from all sources of supply).
 - ☐ To leverage Participant-provided data on direct product rankings (from highly desirable to highly undesirable) in the COVAX Collaboration Platform (CCP) to mark Participants who indicated a product as 'highly undesirable' as ineligible to receive the undesirable product in the algorithm.
- The IAVG agreed with the unique considerations accounted for in this allocation of Sinovac and/or Sinopharm vaccine to participants for Q3-2021, which were:
 - ☐ Direct expressions of product preferences for Sinovac and/or Sinopharm that were facilitated by outreach to all participants,
 - ☐ Confirmations from Optional participants who opted-out of either the Sinopharm deal, the Sinovac deal, or both,
 - ☐ Confirmations of intent to skip this allocation round with no penalty by participants, either directly through the use of the Delay Toggle in the COVAX Collaboration Platform (CCP) or through written confirmation to the Office of the COVAX Facility,
 - ☐ Setting the allocation round minimum to 0 doses rather than 100,800 doses in order to prevent the allocation of very small quantities of doses to participants who have already received large dose donations through COVAX prior to this sixth allocation round and whose total population coverage was far above the achievable equality line reached by all other participants.
- The IAVG agreed with the expected allocation of 2,671,200 doses of J&J to the Humanitarian Buffer.

Considerations for Future Allocation Rounds

- Given the large volumes of vaccine products requiring UCC, the IAVG highlights the need to provide support to Participants to increase equitable access to such products and to reduce the proportion of Participants refusing allocations on the basis of absorptive capacity constraints.
- The IAVG raised concerns about Participants who continue to refuse their allocation round after round. While the group highlights the importance of respecting country decisions, the underscore the need for an assessment to understand more deeply the reality at the country-level that results in such repeated refusals. In this context, the IAVG identifies the difference between system preparedness and political will, highlighting that it may be necessary for Facility Partners to begin engaging with political leadership to investigate if something may be done to reverse such trends.
- For future allocation rounds, the IAVG wishes to investigate the quantity of distinct products allocated to Participants during rounds distributing multiple different vaccines, noting that in the current round, some Participants received up to three different products. Though Participants have the opportunity to indicate that they wish to receive one or several products in the COVAX Collaboration Platform, further thought is needed around the challenge of introducing new products in country, limited supply of diverse products across allocation rounds, and respecting Participants' responses in the CCP. The IAVG notes that several countries are managing multiple products by ensuring that only one product is administered at each vaccine delivery site, which reduces the risk of mix-ups. The IAVG maintains that Participants should be apprised of best practices related to administering multiple COVID-19 vaccine products.
- The IAVG is investigating allocation round sequencing and timing, given the challenges associated with procuring syringes for the Pfizer product. The group will meet to discuss recommendations in the coming weeks.
- Lastly, the IAVG will meet to discuss the issue of sizeable allocations for Participants which did not indicate a voluntary monthly allocation cap in the CCP. The group is of the opinion that the COVAX Facility should refrain from allocating—and subsequently delivering—more quantities of vaccine doses than countries can receive, store, distribute internally and eventually use. The group has asked the JAT to provide more insight into the matter to allow the IAVG to proffer possible solutions.

Annex 1

Overview of Dose Donations Accounted for Before Running R7&8/9

Donor name	Product	Doses Donated	Recipient Participants (n)
Belgium	AstraZeneca – Vaxzevria	1,791,920	7
Canada	AstraZeneca – Vaxzevria	4,084,900	10
Denmark	AstraZeneca – Vaxzevria	882,720	9
France	AstraZeneca – Vaxzevria	13,392,720	36
France	Pfizer BioNTech – Comirnaty	90,090	1
Germany	AstraZeneca – Vaxzevria	11,229,920	20
Greece	AstraZeneca – Vaxzevria	520,800	2
Iceland	AstraZeneca – Vaxzevria	52,020	5
Italy	AstraZeneca – Vaxzevria	7,307,880	11
Japan	AstraZeneca – Vaxzevria	11,253,170	13
New Zealand	AstraZeneca – Vaxzevria	919,200	8
Norway	AstraZeneca – Vaxzevria	1,310,340	11
Portugal	AstraZeneca – Vaxzevria	298,700	1
Spain	AstraZeneca – Vaxzevria	8,105,080	12
Sweden	AstraZeneca – Vaxzevria	2,751,200	16
Switzerland	AstraZeneca – Vaxzevria	439,200	5
United Kingdom	AstraZeneca – Vaxzevria	6,223,680	15
United States	Janssen - Ad26.COV 2-S	29,884,950	41
United States	Moderna – mRNA-1273	54,436,880	23
United States	Pfizer BioNTech – Comirnaty	7,656,480	9
	TOTAL	162,631,850	

Participants are not summed to avoid double-counting.

Reallocation Process for R5 & R6

R5 & R6 Reallocation Summary			
Allocation Round	Participants Refusing (n)	Total Doses Reallocated (n)	Participants Reallocated (n)
COVAX Round 5	13	8,015,670	27
COVAX Round 6	16	32,678,400	32

Reallocation Context
<p><i>R5 Reallocation</i></p> <ul style="list-style-type: none">• A total of 8,015,670 Pfizer doses were reallocated from Participants who refused and who expressed that they were unable to absorb the allocated doses to others who were willing and able to receive shipments.• Some R5 shipments are postponed for delivery in Q4-2021 for Participants not ready to receive them. In accordance with the redistribution process, these doses are not lost for these Participants and will be shipped at a later date. <p><i>R6 Reallocation</i></p> <ul style="list-style-type: none">• A total of 19,598,400 Sinovac and 13,080,000 Sinopharm doses were reallocated both from the Humanitarian Buffer and from Participants who refused their R6 allocation to other Participants who were willing to and able to receive them.• The total amount reallocation from R6 corresponds to roughly 1/3 of the total allocation. As the total quantity of doses up for reallocation exceeded 5M doses, the reallocation proposal was reviewed and validated by the IAVG.

Overview of Allocations to Date (1/2)

Allocation Round	Product Name	WHO EUL Date	Allocation Approval Date	Doses Allocated	Doses Allocated Adjusted	Description
COVAX-1	Pfizer BioNTech – Comirnaty	30 Dec 2020	29 Jan 2021	1,200,420	1,200,420	Pfizer Feb-Mar 2021
COVAX-2	AstraZeneca – Vaxzevria	15 Feb 2021	23 Feb 2021, IAVG	75,996,000	75,484,800	AZ and SII-AZ Jan-May 2021
COVAX-2	SII – Covishield	15 Feb 2021		161,472,000	29,790,600	AZ and SII-AZ Jan-May 2021
COVAX-3	Pfizer BioNTech – Comirnaty	30 Dec 2021	15 Mar 2021, IAVG	14,109,030	14,109,030	Pfizer Apr-Jun 2021
COVAX-4	AstraZeneca – Vaxzevria	15 Feb 2021	8 June 2021	17,366,400	17,066,100	AZ to cover COVAX-2 SII shortage
COVAX-5	Pfizer BioNTech – Comirnaty	30 Dec 2021	15 July 2021, IAVG	72,190,170	72,146,880	Pfizer Jul-Sep 2021
COVAX-6	Sinopharm BIBP	07 May 2021	29 July 2021, IAVG	42,649,200	45,450,000	Sinovac and Sinopharm 2021
COVAX-6	Sinovac	01 June 2021		42,650,400	50,000,400	Sinovac and Sinopharm 2021
COVAX-7	Pfizer BioNTech – Comirnaty	30 Dec 2020	17 Sept 2021, IAVG	45,615,960	45,615,960	Oct 2021 Exceptional Round
COVAX-7	AstraZeneca – Vaxzevria	15 Feb 2021		15,000,000	15,000,000	Oct 2021 Exceptional Round
COVAX-7	Janssen - Ad26.COV 2-S	12 March 2021		3,996,000	3,996,000	Oct 2021 Exceptional Round
COVAX-7	Moderna – mRNA-1273	30 April 2021		10,993,920	10,993,920	Oct 2021 Exceptional Round
COVAX-7	Sinopharm BIBP	07 May 2021		326,400	326,400	Oct 2021 Exceptional Round

Overview of Allocations to Date (2/2)

Allocation Round	Product Name	WHO EUL Date	Allocation Approval Date	Doses Allocated	Doses Allocated Adjusted	Description
ADMIN-1	Pfizer BioNTech – Comirnaty	30 Dec 2020	23 Sept 2021	8,903,700	8,903,700	Previous USG Pfizer donations from DS-5
ADMIN-2	Pfizer BioNTech – Comirnaty	30 Dec 2020	28 Sept 2021	19,338,930	19,338,930	R5 Redistributed Doses
ADMIN-3	AstraZeneca – Vaxzevria	15 Feb 2021	8 Oct 2021	7,996,800	7,996,800	AZ Short Shelf Life
ADMIN-4	Sinopharm BIBP	07 May 2021	8 Oct 2021	10,730,400	10,730,400	Sinovac Option 1 - SFPs
ADMIN-4	Sinovac	01 June 2021	8 Oct 2021	4,039,400	4,039,400	Sinovac Option 1 - SFPs
ADMIN-5	Pfizer BioNTech – Comirnaty	30 Dec 2020	8 Oct 2021	1,167,660	1,167,660	OP Pfizer APA close out
ADMIN-6	Sinovac	01 June 2021	8 Oct 2021	346,800	346,800	SGP increase of Sinovac pro rata share
DOSE_SHARING	Pfizer BioNTech – Comirnaty	30 Dec 2020	Dose donations distributed as of 8 Oct 2021	7,747,740	7,747,740	Donations received and allocated to date
DOSE_SHARING	AstraZeneca – Vaxzevria	15 Feb 2021		65,708,710	65,708,710	Donations received and allocated to date
DOSE_SHARING	Janssen - Ad26.COV 2-S	12 March 2021		24,340,900	24,340,900	Donations received and allocated to date
DOSE_SHARING	Moderna – mRNA-1273	30 April 2021		54,186,700	54,186,700	Donations received and allocated to date
Totals				683,792,580	561,407,190	